<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03365388</url>
  </required_header>
  <id_info>
    <org_study_id>CSG-trail201703</org_study_id>
    <nct_id>NCT03365388</nct_id>
  </id_info>
  <brief_title>A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder</brief_title>
  <official_title>A Validation Study of Sodium Hyaluronate in Patients With Periarthritis of Shoulder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Alge as a positive control drug, in patients with periarthritis of shoulder, in a
      double-blind, controlled manner to study the safety and treatment of Sodium Hyaluronate
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Aerzhi as a positive control drug, in patients with periarthritis of shoulder, in a
      double-blind, controlled manner to study the safety and treatment of Sodium Hyaluronate. Once
      a week, continuous treatment for 5 weeks
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2018</start_date>
  <completion_date type="Anticipated">April 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">April 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The patient was diagnosed with periarthritis of shoulder</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>The evaluation of the subjects will be conducted by the blind researchers. The IMP administration of the subjects will be conducted by non blind researchers or legal staff authorized by the principal investigator (PI)</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Changes of Pain Rating Scale（NRS）</measure>
    <time_frame>Fifth weeks after medication</time_frame>
    <description>At fifth weeks, subjects reported changes in NRS pain scores compared to baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The number of adverse events</measure>
    <time_frame>Fifth weeks after medication</time_frame>
    <description>The number of adverse events：Abnormal laboratory examination results，symptoms or diseases</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">260</enrollment>
  <condition>Periarthritis</condition>
  <arm_group>
    <arm_group_label>Sodium Hyaluronate group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment of periarthritis of shoulder with Sodium Hyaluronate</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aerzhi group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of periarthritis of shoulder with Aerzhi</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sodium Hyaluronate</intervention_name>
    <description>Hyaluronic acid is a component of synovial fluid. N- is glucuronic acid and N-acetylglucosamine repeating disaccharide unit form</description>
    <arm_group_label>Sodium Hyaluronate group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aerzhi</intervention_name>
    <description>Sodium Hyaluronate Injection can cover and protect joint tissue, improve lubrication function, and penetrate degenerative cartilage</description>
    <arm_group_label>Aerzhi group</arm_group_label>
    <other_name>Sodium Hyaluronate Injection</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Based on clinical symptoms and range of motion (ROM) limitation: abduction is not more
             than 135 degrees, external rotation is not more than 20 degrees or the maximum
             internal rotation arrives at the first lumbar spinous process (the tip of the patient
             can touch) to diagnose the patients with periarthritis of shoulder

          2. Signs and symptoms were repeated for 12 weeks or more at the time of signing informed
             consent (12 weeks or more)

          3. At zeroth weeks, according to the pain assessment scale (NRS, range: 0-10), the
             subjects' self rating pain score was no less than 5 points

          4. Fully informed consent signed voluntarily informed consent

        Exclusion Criteria:

          1. Lead to other diseases of shoulder disorders, such as acute rotator cuff tear,
             calcific tendinitis. If the diagnosis is necessary, the MRI scan is performed

          2. Patients who are not suitable for medical treatment (e.g. patients with surgical
             indications)

          3. Patients who received opioids before the first study of the drug

          4. Patients who received the following or more treatment within 2 weeks before the first
             use of the drug(Bilateral or unilateral shoulder joint movement therapy/Treatment of
             periarthritis of shoulder with proprietary Chinese Medicine)

          5. Patients who received the following or more treatment within 4 weeks before the first
             use of the drug(Corticosteroids were injected locally or bilaterally on either side of
             the shoulder or on the other side of the shoulder (bilateral or unilateral shoulder
             joint);Oral corticosteroids, suppositories or intravenous preparations for the
             treatment of glucocorticoids)

          6. Treatment of shoulder joint (bilateral or unilateral) with hyaluronic acid injection
             within 24 weeks before the first study of the drug

          7. It is diagnosed as rheumatic disease

          8. Patients unable to assess their clinical manifestations

          9. Skin disease or skin infection around the injection site can cause the risk of
             injection infection

         10. Severe heart disease, renal failure, hematologic diseases, or diabetes mellitus

         11. There is a history of hypersensitivity to any component in the research drug (IMP)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peixun Zhang, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Peking University People's Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peng Zhang, Doctor</last_name>
    <phone>08601088326550</phone>
    <email>52956255@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Yichong Zhang, Doctor</last_name>
    <phone>08601088326550</phone>
    <email>zhangyichong@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Peking University People's Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>100044</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peixun Zhang, Doctor</last_name>
      <phone>08613611237628</phone>
      <email>zhangpeixun@163.com</email>
    </contact>
    <contact_backup>
      <last_name>Yichong Zhang, Doctor</last_name>
      <phone>08601088326550</phone>
      <email>zhangyichong@163.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Yamamoto M. Sugawara S. Tsukamoto Y. Motegi M. Iwata H. Ryu J. et al. Clinical Evaluation of high molecule weight hyaluronate (NRD101) on osteoarthritis of the knee: a phase III comparative clinical study with ARTZⓇ as a clinical drug. Jpn Pharmacol Ther 1994;22:319-47.</citation>
  </reference>
  <reference>
    <citation>Kurokawa T, Oda H, Mikami Y, Katsumoto H, Clinical Evaluation of high Molecule Weight Sodium Hyaluronate (NRD101) on osteoarthritis of the knee: phase III long-term clinical study. Jpn Pharmacol Ther 1994;22:267-88.</citation>
  </reference>
  <reference>
    <citation>Yamamoto R, Tabata S, Mikasa M, Takagishi K, Clinical evaluation of high molecule sodium hyaluronate (NRD101) on periarthritis scapulohumeralis. Jpn Pharmacol Ther 1993;21:267-80.</citation>
  </reference>
  <reference>
    <citation>Yamamoto R, Tabata S, Mikasa M, Takagishi K, Nakajima M, Dose-range finding study of high molecule weight sodium hyaluronate (NRD101) on periarthritis scapulohumeralis: a multi-center, late phase II clinical study. Jpn Pharmacol Ther 1994;22:351-74.</citation>
  </reference>
  <reference>
    <citation>Yamamoto R, Tabata S, Mikasa M, Takagishi K, Nakajima M, Phase 3 comperative clinical study of high molecular weight sodium hyaluronate (NRD101) with ARTZⓇ on periarthritis scapulohumeralis. Jpn Pharmacol Ther 1994;22:289-317.</citation>
  </reference>
  <reference>
    <citation>Tanaka S, Sohen S, Yamamoto M, Komatsubara Y, Sugawara S, Matsubara T, Additional analysis for a multi-center phase II clinical study of high molecule hyaluronic acid (NRD101) on rheumatoid arthritis. Clinical rheumatology and related research 2000:12: 157-78.</citation>
  </reference>
  <reference>
    <citation>Tanaka S, Sohen S, Yamamoto M, Komatsubara Y, Sugawara S, Matsubara T, et al. Additional analysis for a multi-center phase III comparative clinical study of high molecular hyaluronic acid (NRD101) on rheumatoid arthritis. Clinical rheumatology and related research 2000;12: 179-204</citation>
  </reference>
  <reference>
    <citation>Tanaka S, Sohen S, Yamamoto M, Komatsubara Y, Sugawara S, Matsubara T, Additional analysis for a multi-center, long-term clinical study of high molecule weight hyaluronic acid (NRD101) on rheumatoid arthritis. Clinical rheumatology and related research 2000;12:213-40.</citation>
  </reference>
  <reference>
    <citation>Zhang W, Nuki G, Moskowitz RW, Abramson S, Altman RD, Arden NK, Bierma-Zeinstra S, Brandt KD, Croft P, Doherty M, Dougados M, Hochberg M, Hunter DJ, Kwoh K, Lohmander LS, Tugwell P. OARSI recommendations for the management of hip and knee osteoarthritis: part III: Changes in evidence following systematic cumulative update of research published through January 2009. Osteoarthritis Cartilage. 2010 Apr;18(4):476-99. doi: 10.1016/j.joca.2010.01.013. Epub 2010 Feb 11. Review.</citation>
    <PMID>20170770</PMID>
  </reference>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2017</study_first_submitted>
  <study_first_submitted_qc>December 6, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 7, 2017</study_first_posted>
  <last_update_submitted>December 6, 2017</last_update_submitted>
  <last_update_submitted_qc>December 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 7, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University People's Hospital</investigator_affiliation>
    <investigator_full_name>pengzhang</investigator_full_name>
    <investigator_title>Doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Periarthritis</mesh_term>
    <mesh_term>Bursitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyaluronic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

